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Summary
Reporting and publication bias is a well-known problem in
meta-analysis and healthcare research. In 2002 we conduc-
ted a meta-analysis on the effects of erythropoiesis-stimu-
lating agents (ESAs) on overall survival in cancer patients,
which suggested some evidence for improved survival in
patients receiving ESAs compared with controls. However,
a meta-analysis of individual patient data conducted sever-
al years later showed the opposite of our first meta-analys-
is, that is, evidence for increased on-study mortality and re-
duced overall survival in cancer patients receiving ESAs.
We aimed to determine whether the results of our first
meta-analysis could have been affected by publication and
reporting biases and, if so, whether timely access to clin-
ical study reports and individual patient data could have
prevented this. We conducted a hypothetical meta-analys-
is for overall survival including all studies and study data
that could have been available in 2002, at the time when
we conducted our first meta-analysis. Compared with our
original meta-analysis, which suggested an overall surviv-
al benefit for cancer patients receiving ESAs [hazard ratio
(HR) 0.81, 95% confidence interval (CI) 0.67‒0.99], our
hypothetical meta-analysis based on the results of all stud-
ies conducted at the time of the first analysis did not show
evidence for a beneficial effect of ESAs on overall surviv-
al (HR 0.97, 95% CI 0.83‒1.12). Thus we have to con-
clude that our first meta-analysis showed misleading over-
all survival benefits due to publication and reporting biases,
which could have been prevented by timely access to clin-
ical study reports and individual patient data. Unrestricted
access to clinical study protocols including amendments,
clinical study reports and individual patient data is needed
to ensure timely detection of both beneficial and harmful
effects of healthcare interventions.
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Meta-analyses and the threat of
reporting and publication biases
The large number of studies conducted in medical research
and their sometimes conflicting results make it difficult for
healthcare professionals and policy makers to reach well-
informed decisions. Meta-analyses offer a possible solu-
tion, as they provide an overall effect estimate by pool-
ing results from different studies dealing with the subject
in question. In this way they may overcome problems that
individual studies might have, such as small sample size
and low statistical power, and may provide answers when
the results of individual studies are conflicting. A correctly
conducted meta-analysis should be preceded by a system-
atic review of the literature, which aims to identify all the
available studies on the subject. It is conducted in a trans-
parent and replicable manner, and the studies are selected
and evaluated according to predefined criteria.
Meta-analyses, however, might also yield misleading res-
ults. There are three main reasons why this could happen:
(a) poor quality of the included studies; (b) heterogeneity
between the studies; and (c) publication and reporting bi-
ases [1]. As each individual study affects the overall result
of a meta-analysis, its quality should be assessed and taken
into account. Study quality could be evaluated by using
various criteria such as method of randomisation and al-
location concealment, blinding of patients and outcome as-
sessors, use of intention-to-treat analysis, etc. In addition,
a high degree of heterogeneity between studies can also af-
fect the overall result and researchers should seek to ex-
plain heterogeneity by stratifying results according to pre-
specified groups, for instance according to type of cancer,
or type of chemotherapy, etc.
The term “publication bias” refers to the fact that not all
studies are published and that publication of studies fol-
lows a pattern that cannot be attributed to chance: studies
with positive results tend to be published more often and
earlier than studies with negative results [2, 3]. A longitud-
inal study of the publication outcome of clinical trial proto-
cols submitted to five ethics committees showed that trials
were 2.6 times more likely to be published if they repor-
ted statistically significant results [4]. Bourgeois and col-
leagues [5], on the basis of a sample of more than 500
registered clinical trials, found that studies funded by in-
dustry were more likely to be published if they reported
positive results. Reporting bias refers to the selective re-
porting of outcomes in a published study. For instance,
some outcomes that had been defined in the protocol might
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not be reported [6], or the results reported are derived from
per-protocol analyses rather than intention-to-treat analyses
[7]. This kind of bias also seems to follow a pattern,
whereby mainly the most statistically significant results or
the ones meeting the authors’ assumptions are reported [8].
The case of erythropoiesis-stimulating
agents in cancer patients
In 2002 we conducted a meta-analysis on the effects of
erythropoiesis-stimulating agents (ESAs) in cancer pa-
tients. ESAs are recombinant human proteins resembling
erythropoietin, which is a human hormone produced
mainly in the kidney and which stimulates the production
of red blood cells. ESAs were licensed to treat cancer-re-
lated anaemia in 1990. There are several short- or long-
acting ESAs, with the most commonly used ones being
epoetin-α or epoetin-β and darbepoetin. Since their intro-
duction for the treatment of cancer-related anaemia, numer-
ous randomised controlled trials and systematic reviews
have been conducted, in order to assess their efficacy and
their potential side effects [9–28]. Our first meta-analysis
in 2002 [12] showed that besides reducing the risk and the
need for red blood cell transfusions, ESAs might also im-
prove overall survival (see fig. 1). The result was mainly
driven by one large study conducted by Littlewood and col-
leagues in 2001 [29]. The study produced some evidence
that patients with solid and haematological malignancies
Figure 1
Forest plot for overall survival based on data from our first meta-
analysis [12].
Figure 2
Funnel plot for overall survival based on data from our first meta-
analysis [12].
who received ESAs experienced improved overall surviv-
al compared with controls. The p-value of the trial was of
borderline significance (p = 0.052). However, the endpoint
of overall survival was introduced as a protocol amend-
ment after the study had been started. Including adjusted
data from this trial and data from another 18 trials with
a total of 2,805 patients, our meta-analysis showed some
evidence for improved overall survival in patients receiv-
ing ESAs (hazard ratio (HR) 0.81, 95% confidence interval
(CI) 0.67‒0.99 using adjusted survival estimates and HR
0.84, 95% CI 0.69‒1.02 using unadjusted survival estim-
ates from Littlewood et al. [29]). In other words, when we
pooled the results from individual studies for our first meta-
analysis, we found evidence for an overall survival benefit
for cancer patients receiving ESAs. Of note, there was no
evidence of a publication bias (p-value for regression test =
0.481) (see fig. 2). This finding was supported by biologic-
al hypotheses. There was evidence from animal models and
studies in humans that anaemia might result in a poorer re-
sponse to chemotherapy or radiotherapy owing to increased
tumour hypoxia [30–34]. Consequently, researchers hypo-
thesised that targeting cancer-related anaemia might also
improve tumour response and overall survival.
However, already in 2003 the findings of our first meta-
analysis were contradicted by two large randomised con-
trolled trials that showed reduced survival for the ESA
group in patients with metastatic breast cancer receiving
chemotherapy [35] and patients with head and neck cancers
receiving radiotherapy [36]. These unfortunate findings
were followed by several other trials showing detrimental
survival results for cancer patients receiving ESAs, as com-
pared with controls [37–41]. When updating our meta-ana-
lysis on overall survival in 2006, these findings from single
studies were consolidated but still uncertain: the HR for
overall survival was 1.08 (95% CI 0.99‒1.18, 42 trials and
8,167 patients), making the overall survival benefit we had
previously reported questionable. In this situation we de-
cided to retrieve the individual patient data (IPD) for all
randomised controlled trials (RCTs) of the effects of ESAs
compared with standard care in cancer patients. We invited
independent investigators and pharmaceutical companies
(Johnson & Johnson, Roche, Amgen) to participate in this
project and to contribute their trial data. In 2008 we re-
ceived the IPD as requested, as well as corresponding study
protocols, protocol amendments and clinical study reports
for 53 RCTs including 13,933 patients [28]. Based on these
data and documents we conducted a meta-analysis on the
effects of ESAs on on-study mortality and overall survival,
which was published in 2009 [28]. The use of IPD allowed
us to overcome certain limitations of literature-based meta-
analyses, such as the use of aggregated data, heterogeneous
endpoints across studies and the inability to assess differ-
ences across subgroups. For this update we differentiated
mortality during the active study period from overall sur-
vival, defined as deaths during the longest follow up avail-
able. This update confirmed the previously noted trends:
ESAs increased on-study mortality in cancer by a factor
of 1.17 (HR 1.17, 95% CI 1.06‒1.30) and there was some
evidence for reduced overall survival (HR 1.06, 95% CI
1.00‒1.12).
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A hypothetical study
Introduction
To determine whether the results of our first meta-analysis
[12] had been affected by publication and reporting biases,
and if timely access to clinical study reports and IPD could
have prevented this, we conducted a hypothetical meta-
analysis for overall survival and on-study mortality includ-
ing studies and study data which could have been available
in 2002, at the time when we conducted our first meta-ana-
lysis.
Methods
In this hypothetical meta-analysis, we included studies that
recruited patients until the end of 1999. We chose this time-
frame because it closely corresponds to the studies we in-
cluded in the first, literature-based meta-analysis, that is,
studies published up to the beginning of 2002. We identi-
fied eligible studies on the basis of the meta-analyses con-
Figure 3
Forest plot for overall survival based on data from our first meta-
analysis [12] adding missing studies and using results from
individual patient data review [27, 28].
Figure 4
Funnel plot for overall survival based on data from our first meta-
analysis [12] adding missing studies and using results from
individual patient data review [27, 28].
ducted previously [12, 14, 28]. In these meta-analyses [12,
14, 28] we included randomised controlled trials compar-
ing ESAs with placebo or best usual care in cancer patients
who were anaemic or at risk of developing cancer-related
anaemia, and who were or were not receiving anticancer
treatment. We conducted systematic searches using elec-
tronic databases (Medline, Embase, Cochrane Library and
databases of conference proceedings), as well as docu-
ments from Oncology Drug Advisory Committee (ODAC)
hearings [42]. For the first, literature-based review, we also
obtained unreported data from the investigators. For the
IPD review we obtained raw study data, study protocols,
their amendments and clinical study reports from manu-
facturers and independent investigators. For the literature-
based meta-analyses we used overall survival defined as
the longest follow up available. For the IPD meta-analysis
we used overall survival and in addition on-study mortality
defined as death from any cause during the active study
period plus 30 days. Details of these meta-analyses are re-
ported elsewhere [12, 14, 28].
For the hypothetical meta-analysis we extracted overall
survival and on-study mortality data from these three meta-
analyses [12, 14, 28]. Whenever we had more than one res-
ult for a given study the following hierarchy applied: (1.)
data and results taken from IPD review; (2.) data and res-
ults provided by study authors for previous meta-analyses;
(3.) data and results as reported in the literature. We com-
pared results from the different reviews for a given study,
discrepant data and results were noted and reasons for dis-
crepancies investigated and reported. Overall survival and
on-study mortality was assessed as time-to-event analysis
using hazard ratios. We calculated effect estimates and 95%
confidence intervals (CIs) using fixed effects models.
Results
Our first, literature-based meta-analysis evaluated 19 trials
including 2,805 patients for overall survival [12]. We ob-
tained overall survival data either from the literature [29,
43–45] or from study investigators [46–60]. We found a
HR of 0.81 (95% CI 0.67‒0.99, figs 1 and 2), favouring
ESAs. For the hypothetical meta-analysis we identified 25
eligible studies (3,664 patients in total; 2,155 randomised
to ESA; 1,509 randomised to control), which recruited pa-
tients up to the end of 1999. Of these, 19 trials had been
included in the overall survival analysis of the first meta-
analysis. Another six studies were not included in the first
meta-analysis for the following reasons: One study [61]
had been included in the first review [12], however, since
survival data were not reported or provided by the study
authors, the study was not included in the overall survival
analysis. Another study [62] was published after 2002 and
was therefore not identified for the first review [12]. Four
studies [63–66] were completed at the time of the first re-
view [12], but survival or any other study data had not yet
been published. The survival results for these studies be-
came available through ODAC reports published in 2003
[67] and the IPD meta-analysis published in 2009 [28].
Five of these six studies showed detrimental findings, that
is, worse survival in patients receiving ESAs than in con-
trols. For the 19 studies which had already been included
in the first review [12] we compared the results reported in
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the different sources. For the six studies [43, 45, 49, 54, 55,
58], no additional data were retrieved for the IPD review
because the studies were too small for inclusion [27, 28].
The results for these six studies [43, 45, 49, 54, 55, 58] are
therefore identical in the first review and the hypothetic-
al meta-analysis. For 13 studies [29, 44, 46–48, 50–53, 56,
57, 59, 60] we had results stemming from the first review
[12] and the IPD meta-analysis [28]. For three studies the
number of patients randomised and the number of events
were identical and there were only minor differences in ef-
fect estimates (HRs or CIs) [29, 46, 48]. For the other ten
studies we noted discrepant results, that is, the data repor-
ted in the literature or provided by the study authors for the
first review [12] were not identical to the overall survival
estimates generated in the IPD review [28]. Discrepancies
concerned the number of patients randomised per study
arm, the number of deaths per study arm and the repor-
ted HRs plus CIs, for details see attached data table 1. Dif-
ferences were explained by differing definitions of end of
study in three studies [47, 50, 52], longer follow up or up-
dated study information available for IPD for four studies
[44, 57, 59, 60]. For two studies IPD analysis was based on
intention-to-treat whereas previously included results were
based on a safety population including only patients who
had received at least one dose of the drug [53, 56]. For an-
other study differences are explained by use of different in-
clusion criteria in the first review and the IPD review [51].
The results obtained for the IPD review [28] were worse (a
HR which was less favourable than the previously reported
HR) in seven studies [44, 47, 50, 51, 56, 57, 59] and better
(a HR which was more favourable compared to the previ-
ously reported HR) in three studies [52, 53, 60].
For the hypothetical meta-analysis we included the avail-
able data stepwise into the original review conducted in
2002. Firstly, we added published data for “late” public-
ations [62] and IPD for unreported outcomes from pub-
lished [61, 63] and unpublished studies [64–66]. This resul-
ted in the addition of six more studies, which means that in
2002 24% of the available studies were missing. Five out of
these six studies were sponsored by pharmaceutical com-
panies. By including these missing studies the hazard ratio
changed from 0.81 (95% CI 0.67‒0.99) to 0.88 (95% CI
0.73‒1.05). Moving one step further, we replaced the pub-
lished data of our first analysis [12] with IPD [27, 28]. This
resulted in replacing data from 13 studies (or from 52% of
all the included studies). The new HR was 0.97 (95% CI
0.83‒1.12, figs 3 and 4), showing no overall survival bene-
fit for patients receiving ESAs compared to controls. In a
sensitivity analysis we conducted a similar analysis for on-
study mortality and found similar results (data on file).
Discussion
Compared with our original meta-analysis, which sugges-
ted an overall survival benefit for cancer patients receiving
ESAs (HR 0.81, 95% CI 0.67‒0.99) [12], our hypothetical
meta-analyses based on the results of all studies conducted
at the time of the first analysis did not show evidence for
a beneficial effect of ESAs on overall survival (HR 0.97;
95% CI 0.83‒1.12). This suggests that our first meta-ana-
lysis [12] showed misleading overall survival benefit ow-
ing to publication and reporting biases, which could have
been prevented by timely access to IPD and clinical study
reports. Based on a series of meta-analyses with access to
published reports and IPD, our study demonstrates the im-
pact of publication and reporting biases on the perceived
effects of ESAs on survival in cancer patients. We were
able to show this effect by using a large number of stud-
ies. Compared with our original analysis we increased the
number of studies by 25% and replaced 52% of the data
with results generated in an IPD meta-analysis [27, 28].
Our case study, however, has limitations. For six studies
[43, 45, 49, 54, 55, 58] we did not have IPD; however,
these studies were small and a large effect on the overall
results is unlikely. We investigated overall survival and on-
study mortality, and we do not know whether the publica-
tion and reporting biases would affect other outcomes in a
similar way. However, we recently updated several clinical
outcomes for our Cochrane Review [14, 68] based on the
published literature. With few exceptions study outcomes
were underreported leading to overestimates of both bene-
ficial and harmful effects of ESAs [68].
How to address publication and
reporting biases?
Our case study adds another example to the large body
of evidence on publication and reporting biases [2–4, 8,
69–71]. Funnel plots offer a way to explore the probability
of publication bias; however, they only demonstrate but do
not solve potential publication biases. They can also pro-
duce false negative results. For example, the funnel plot
generated for our first meta-analysis did not indicate a pub-
lication bias. In 2004, the International Committee of Med-
ical Journal Editors produced a statement requiring trials to
have been registered in a registry before being considered
for publication [72]. Two years after its implementation,
more trials were registered than in the past [73]. However,
this measure did not help to reduce selective reporting of
outcomes leading to reporting bias, since this statement did
not require reporting of study results. A study by Huic et
al. [74] assessed about 150 reports from RCTs and found
that almost 40% of the assessed trials had discrepancies
between their registered and reported primary outcomes,
and almost 65% had discrepancies in the secondary out-
comes. Most of these discrepancies were due to post-hoc
reporting of outcomes in the publications that had not been
listed in the registry. There is some evidence that, specific-
ally for adverse events, unpublished data might allow a
more accurate estimate than the published data [75]. This
kind of discrepancy has led to the recognition that not only
registration of the trial but also complete reporting of study
results needs to be ensured. The US FDA Amendments Act
of 2007 requires the publication of the main trial results in
a standardised summary report [76–79]. However, it does
not require the publication of the entire clinical study re-
port or the release of the IPD. The European Medicines
Agency (EMA), recognising that the current state of dis-
closure of important study documents is no longer desir-
able [80], has changed its policy on document access [81].
With the new policy the EMA will release documents upon
request provided that the EMA’s authorisation procedures
on a given drug have been finalised.
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There is an on-going debate as to whether the release of
clinical study reports including tabulated listings of an-
onymised IPD is sufficient, or whether IPD in electronic
databases suitable for re-analysis of the data are needed
[80, 82]. Access to IPD permits researchers to define uni-
form study endpoints across studies, to conduct intention-
to-treat analyses standardised across trials and to include
additional information gained through longer follow up
[83]. Access to well-reported clinical study protocols and
reports in addition to the IPD are essential to fully under-
stand the nature and quality of the IPD [84, 85]. Whether,
in contrast, access to clinical study reports providing sum-
mary estimates would be sufficient to allow an adequate
evaluation of the drug remains questionable and has to our
best knowledge not yet been investigated.
Is meta-analysis losing its credibility?
In a recently published opinion paper in Nature Medicine
the authors pointed out that with a lack of robust evidence
and a reasonable minimum amount of data, meta-analyses
could lose credibility [86]. We agree that robust data are
needed to generate meta-analyses that help to make well-
informed decisions on healthcare interventions. We also
agree that meta-analyses based on biased data sets can pro-
duce distorted and misleading results. However, we would
like to emphasise that a lack of robust data, either due to
a lack of high quality studies or due to reporting and pub-
lication biases, is not a problem of meta-analysis per se;
it is a problem of healthcare and medical research. Meta-
analyses together with funnel plots and regression tests are
instruments that allow the assessment of the quality of the
studies and detection of publication or reporting biases, ac-
tually making the absence of studies and study results vis-
ible. If the published data are so incomplete that we cannot
use them for a meta-analysis how can we possibly use them
Table 1: Comparison of study data used for our first meta-analysis [87] on the effects of erythropoiesis-stimulating agents on cancer (conducted in 2002) and
a hypothetical meta-analysis including all data which could have been available at the time of the first meta-analysis.
Data as used in the first review [87] Hypothetical meta-analysis Comment
Author, year of
publication
ESA
group
n /N
Controls
n /N
Hazard ratio
[95% Confidence
interval]
ESA
group
n /N
Controls
n /N
Hazard ratio
[95% confidence
interval]
Abels 1993 13/65 13/59 0.89 [0.37, 2.10] 13/65 12/59 0.96 [0.44, 2.10] Different end of study definition
Bamias 2003 NA NA NA 7/72 4/72 1.80 [0.53, 6.12] Not available in 2002
Boogaerts 2003 8/133 8/129 1.02 [0.38, 2.72] 16/132 12/127 1.53 [0.72, 3.26] For IPD longer follow-up available
Cascinu 1994 0/50 0/50 Could not be estimated 0/50 0/50 Not estimable Same data
Case 1993 10/81 9/76 1.05 [0.40, 2.73] 10/81 9/76 1.11 [0.45, 2.73] Number of patients and events identical,
minor differences in HR and CI
Cazzola 1995 2/57 1/29 0.06 [0.00, 3.53] 5/114 3/29 0.69 [0.13, 3.57] IPD includes 2 study groups with low dose
ESA, which had been excluded from the
2002 review
Dammacco 2001 1/69 7/76 0.23 [0.05, 0.94] 1/69 7/76 0.23 [0.06, 0.90] Number of patients identical, minor
differences in CI
Del Mastro 1997 1/31 3/31 0.36 [0.05, 2.53] 1/31 3/31 0.36 [0.05, 2.53] Same data
Dunphy 1999 0/15 1/15 0.14 [0.00, 6.82] 0/15 1/15 0.14 [0.00, 6.82] Same data
EPO-INT-1 – – – 11/165 3/81 1.88 [0.63, 5.64] Not available in 2002
EPO-INT-3 – – – 9/135 3/65 1.55 [0.47, 5.10] Not available in 2002
Henry 1995 8/67 10/65 0.75 [0.28, 2.01] 7/67 10/65 0.68 [0.26, 1.77] Different end of study definition
Huddart 2002 – – – 8/48 8/47 1.19 [0.44, 3.21] Not available in 2002
Kurz 1997 0/23 0/12 Could not be estimated 0/23 0/12 Not estimable Same data
Littlewood 2001 155/251 82/124 0.81 [0.62, 1.06 ]* 155/251 82/124 0.80 [0.61, 1.05] Number of patients identical, minor
differences in HR and CI
0.76 [0.58, 1.00]**
Oberhoff 1998 5/114 12/104 0.38 [0.15, 0.99] 9/116 10/111 0.62 [0.24, 1.59] IPD based on ITT, published data based on
safety
Osterborg 1996 25/95 12/49 1.07 [0.54, 2.11] 26/99 14/49 0.94 [0.49, 1.81] IPD based on ITT, published data based on
safety
Osterborg 2002 21/170 19/173 1.13 [0.61, 2.09] 110/173 109/176 1.04 [0.80, 1.36] Longer follow-up; IPD based on ITT,
published data based on safety
P-174 – – – 1/33 1/12 0.44 [0.03, 7.27] Not available in 2002
Quirt 1996 NR NR NR 2/28 0/28 5.90 [0.36, 97.07] Not available in 2002
Rose 1994 11/142 4/79 1.52 [0.51, 4.53] 16/142 6/79 1.66 [0.70, 3.92] Different end of study definition
Ten Bokkel 1998 4/87 2/33 0.80 [0.14, 4.70] 6/87 2/33 1.27 [0.26, 6.34] For IPD longer follow-up available
Thatcher 1999 6/86 3/44 1.01 [0.24, 4.27] 7/86 3/44 1.13 [0.29, 4.36] IPD contains updated study data
Thompson 2000 3/45 0/21 4.52 [0.38, 53.37] 3/45 0/21 4.52 [0.38, 53.37] Same data
Throuvalas 2000 0/28 1/27 0.13 [0.00, 6.55] 0/28 1/27 0.13 [0.00, 6.55] Same data
Total (19 studies) 273/1609 187/1196 0.81 [0.67, 0.99] 423/2155 303/1509 0.97 [0.83, 1.12]
ESA = erythropoiesis-stimulating agents; n = number of events; N = number of participants; * unadjusted calculated based on p-value from Kaplan Meier estimate
published in Littlewood 2001 [88]; ** adjusted HR as reported in Littlewood 2001. NR = not reported; NA = not available: study not published in 2002, IPD = individual
patient data; HR = hazard ratio; CI = confidence interval; bold font indicates results which differed between the first review and the IPD review
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to make healthcare decisions for patients, with or without
meta-analysis?
Our study is yet another indication that publication and
reporting biases are main obstacles to the efficient use
of healthcare interventions. We strongly believe that these
problems cannot be eliminated by the registration of trials
and the standardised but limited reporting of trial results.
Unrestricted access to clinical study protocols including
amendments, to clinical study reports as well as to IPD is
needed to ensure timely detection of both beneficial and
harmful effects of health care interventions.
Funding / potential competing interests: No financial support
and no other potential conflict of interest relevant to this article
was reported.
Correspondence: Thomy Tonia, MSc, University of Bern,
Institute of Social and Preventive Medicine, Finkenhubelweg 11,
CH-3012 Bern, Switzerland, ttonia[at]ispm.unibe.ch
References
1 Nordmann A, Kasenda B, Briel M. Meta-analyses: what they can and
cannot do. Swiss Med Wkly. 2012;142(w13518).
2 Stern JM, Simes RJ. Publication bias: evidence of delayed publication
in a cohort study of clinical research projects. BMJ.
1997;315(7109):640–5.
3 Song F, Parekh S, Hooper L, Loke Y, Ryder J, Sutton A, et al. Dissemin-
ation and publication of research findings: an updated review of related
biases. Health Technol Assess. 2010;14(8):1–220.
4 von Elm E, Rollin A, Blumle A, Huwiler K, Witschi M, Egger M.
Publication and non-publication of clinical trials: longitudinal study
of applications submitted to a research ethics committee. Swiss Med
Wkly. 2008;138(13-14):197–203.
5 Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug
trials registered in ClinicalTrials.gov. Ann Intern Med.
2010;153(3):158–66.
6 Chan AW, Altman DG. Identifying outcome reporting bias in random-
ised trials on PubMed: review of publications and survey of authors.
BMJ. 2005;330(7494):753.
7 Hollis S, Campbell F. What is meant by intention to treat analysis?
Survey of published randomised controlled trials. BMJ.
1999;319(7211):670–4.
8 Norris SL, Holmer HK, Ogden LA, Fu R, Abou-Setta AM, Viswanath-
an MS, et al. Selective Outcome Reporting as a Source of Bias in
Reviews of Comparative Effectiveness. 2012 Aug.
9 Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-
beta on survival, tumour progression and thromboembolic events in pa-
tients with cancer: an updated meta-analysis of 12 randomised con-
trolled studies including 2301 patients. Br J Cancer. 2008;99(1):14–22.
10 Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason
KJ, et al. Venous thromboembolism and mortality associated with re-
combinant erythropoietin and darbepoetin administration for the treat-
ment of cancer-associated anemia. JAMA. 2008;299(8):914–24.
11 Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett
CL, et al. Epoetin treatment of anemia associated with cancer therapy: a
systematic review and meta-analysis of controlled clinical trials. J Natl
Cancer Inst. 2001;93(16):1204–14.
12 Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Ben-
nett C, et al. Recombinant human erythropoietin and overall survival in
cancer patients: results of a comprehensive meta-analysis. J Natl Can-
cer Inst. 2005;97(7):489–98.
13 Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et
al. A systematic review and economic evaluation of epoetin alpha, epo-
etin beta and darbepoetin alpha in anaemia associated with cancer, es-
pecially that attributable to cancer treatment. Health Technol Assess.
2007;11(13):1-iv.
14 Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J,
et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane
Database Syst Rev 2006;3:CD003407.
15 Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J,
et al. Recombinant human erythropoietins and cancer patients: updated
meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst.
2006;98(10):708–14.
16 Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A,
et al. Comparative effectiveness of epoetin and darbepoetin for man-
aging anemia in patients undergoing cancer treatment. Comparative ef-
fectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield
Association Technology Evaluation Center. Evidence-based Practice
Center under contract No. 290-02-0026). Rockville, MD. Agency for
Healthcare Research and Quality. May 2006. Available at:
www.effectivehealthcare.ahrq.gov/reports/final.cfm.
17 Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd
A, et al. Benefits and harms of erythropoiesis-stimulating agents for
anemia related to cancer: a meta-analysis. CMAJ.
2009;180(11):E62–E71.
18 Tonelli M, Lloyd A, Lee H, Wiebe N, Hemmelgarn B, Reiman T, et
al. Erythropoiesis-stimulating agents for anemia of cancer or of chemo-
therapy: systematic review and economic evaluation. Ottawa: Canadian
Agency for Drugs and Technologies in Health; 2009. Report No.: Tech-
nology report number 119. -. p.
19 Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT.
Clinical benefits and risks associated with epoetin and darbepoetin in
patients with chemotherapy-induced anemia: a systematic review of the
literature. Clin Ther. 2006;28(6):801–31.
20 Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic
review and meta-analysis of the pharmacological treatment of cancer-
related fatigue. J Natl Cancer Inst. 2008;20;100(16):1155–66.
21 Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy
for the management of cancer-related fatigue. Cochrane Database Syst
Rev. 2010;(7):CD006704.
22 Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU. Effect of
treatment with epoetin beta on short-term tumour progression and sur-
vival in anaemic patients with cancer: A meta-analysis. Br J Cancer.
2006;95(11):1467–73.
23 Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treat-
ment in patients with cancer chemotherapy-induced anaemia: the im-
pact of initial haemoglobin and target haemoglobin levels on survival,
tumour progression and thromboembolic events. Br J Cancer.
2009;101(12):1961–71.
24 Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH,
Fleishman A, et al. Pooled analysis of individual patient-level data from
all randomized, double-blind, placebo-controlled trials of darbepoetin
alfa in the treatment of patients with chemotherapy-induced anemia. J
Clin Oncol. 2009;27(17):2838–47.
25 Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et
al. Erythropoiesis-stimulating agents in oncology: a study-level meta-
analysis of survival and other safety outcomes. Br J Cancer.
2010;19;102(2):301–15.
26 Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of
erythropoietin receptors and erythropoiesis-stimulating agents on dis-
ease progression in cancer. Br J Cancer. 2012;106(7):1249–58.
27 Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J,
et al. Recombinant human erythropoiesis-stimulating agents and mor-
tality in patients with cancer: a meta-analysis of randomised trials. Lan-
cet. 2009;373(9674):1532–42.
28 Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld
J, et al. Erythropoietin or Darbepoetin for patients with cancer – meta-
analysis based on individual patient data. Cochrane.Database.Syst.Rev.
2009;(3):CD007303.
29 Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Ef-
fects of epoetin alfa on hematologic parameters and quality of life
in cancer patients receiving nonplatinum chemotherapy: results of a
randomized, double-blind, placebo-controlled trial. J Clin Oncol.
2001;19(11):2865–74.
Review article: Current opinion Swiss Med Wkly. 2013;143:w13776
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 6 of 11
30 Frommhold H, Guttenberger R, Henke M. The impact of blood hemo-
globin content on the outcome of radiotherapy. The Freiburg experien-
ce. Strahlenther Onkol. 1998;174(Suppl 4):31–4.
31 Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze
M, et al. Intratumoral pO2 predicts survival in advanced cancer of the
uterine cervix. Radiother Oncol. 1993;26(1):45–50.
32 Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intrat-
umoral pO2-measurements as predictive assay in the treatment of car-
cinoma of the uterine cervix. Radiother Oncol. 1999;53(2):99–104.
33 Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, et al.
Impact of hemoglobin level and use of recombinant erythropoietin on
efficacy of preoperative chemoradiation therapy for squamous cell car-
cinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys.
2001;50(3):705–15.
34 Silver DF, Piver MS. Effects of recombinant human erythropoietin on
the antitumor effect of cisplatin in SCID mice bearing human ovarian
cancer: A possible oxygen effect. Gynecol Oncol. 1999;73(2):280–4.
35 Leyland-Jones B. Breast cancer trial with erythropoietin terminated un-
expectedly. Lancet Oncol. 2003;4(8):459–60.
36 Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et
al. Erythropoietin to treat head and neck cancer patients with anaemia
undergoing radiotherapy: randomised, double-blind, placebo-controlled
trial. Lancet. 2003;362(9392):1255–60.
37 Smith RE, Jr., Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE,
et al. Darbepoetin alpha for the treatment of anemia in patients with
active cancer not receiving chemotherapy or radiotherapy: results of
a phase III, multicenter, randomized, double-blind, placebo-controlled
study. J Clin Oncol. 2008;26(7):1040–50.
38 Hedenus M, Adriansson M, San MJ, Kramer MH, Schipperus MR,
Juvonen E, et al. Efficacy and safety of darbepoetin alfa in anaemic
patients with lymphoproliferative malignancies: a randomized, double-
blind, placebo-controlled study. Br J Haematol. 2003;122(3):394–403.
39 Overgaard J, Hoff CM, Hansen HS, Specht L, Overgaard M, Grau C,
et al. Randomized study of darbepoetin alfa as modifier of radiotherapy
in patients with primary squamous cell carcinoma of the head and neck
(HNSCC): Final outcome of the DAHANCA 10 trial. In 2009. p. abstr
6007.
40 Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al.
Randomized, double-blind, placebo-controlled trial of erythropoietin in
non-small-cell lung cancer with disease-related anemia. J Clin Oncol.
2007;20;25(9):1027–32.
41 Goss G, Feld R, Bezjak A, Perry G, Melosky B, Smith C, et al. O-154
Impact of maintaining Hb with epoetin alfa on time toprogression
(TTP), overall survival (OS), quality of life (QOL) and transfusion re-
duction in limited disease SCLC patients. Lung Cancer 49[Supplement
2], S53. 2005.
42 Luksenburg H, Weir A, Wager R. Safety concerns associated with
Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho
Biotech, L.P., for the treatment of anemia associated with cancer
chemotherapy. 2004. Department of Health and Human Services, Food
and Drug Administration, Center for Drug Evaluation and Research,
Oncologic Drugs Advisory Committee.
43 Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG,
Boyd JH. Erythropoietin reduces anemia and transfusions: A random-
ized trial with or without erythropoietin during chemotherapy. Cancer.
1999;86(7):1362–7.
44 Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant
R, et al. Epoetin alpha prevents anaemia and reduces transfusion re-
quirements in patients undergoing primarily platinum-based chemo-
therapy for small cell lung cancer. Br J Cancer. 1999;80(3-4):396–402.
45 Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson
RA, et al. Effect of recombinant human erythropoietin combined with
granulocyte/ macrophage colony-stimulating factor in the treatment of
patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
Blood. 2000;95(4):1175–9.
46 Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the
treatment of anaemia of multiple myeloma. Br J Haematol.
2001;113(1):172–9.
47 Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer.
1993;29A(Suppl 2):S2-8.:S2–S8.
48 Case DC, Jr., Bukowski RM, Carey RW, Fishkin EH, Henry DH, Ja-
cobson RJ, et al. Recombinant human erythropoietin therapy for an-
emic cancer patients on combination chemotherapy. J Natl Cancer Inst.
1993;19;85(10):801–6.
49 Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant
Human Erythropoietin Treatment in Cisplatin-Associated Anemia: A
Randomized, Double-Blind Trial With Placebo. J Clin Oncol.
1994;12:1058–62.
50 Rose E, Rai K, Revicki D, et al. Clinical and health status assessments
in anemic chronic lymphocytic leukemia (CLL) patients treated with
epoetin alfa (EPO). Blood. 1994;84(10 Suppl 1):526a.
51 Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler
L, et al. Recombinant human erythropoietin in the anemia associated
with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and
identification of predictors of response. Blood. 1995;86(12):4446–53.
52 Henry DH, Abels RI. Recombinant human erythropoietin in the treat-
ment of cancer and chemotherapy-induced anemia: results of double-
blind and open-label follow-up studies. Semin Oncol. 1994;21(2 Suppl
3):21–8.
53 Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Julius-
son G, et al. Recombinant human erythropoietin in transfusion-depend-
ent anemic patients with multiple myeloma and non-Hodgkin’s lymph-
oma – a randomized multicenter study. The European Study Group
of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and
Non-Hodgkin’s Lymphoma. Blood. 1996;87(7):2675–82.
54 Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti
W, et al. Randomized phase III trial evaluating the role of erythropoietin
in the prevention of chemotherapy-induced anemia. J Clin Oncol.
1997;15(7):2715–21.
55 Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, et
al. Erythropoietin treatment under polychemotherapy in patients with
gynecologic malignancies: a prospective, randomized, double-blind
placebo-controlled multicenter study. Gynecol Oncol.
1997;65(3):461–6.
56 Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann
U, et al. Recombinant human erythropoietin in the treatment of
chemotherapy-induced anemia and prevention of transfusion require-
ment associated with solid tumors: a randomized, controlled study. Ann
Oncol. 1998;9(3):255–60.
57 ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G,
Breed WP, Hillen HF, et al. Controlled multicentre study of the influen-
ce of subcutaneous recombinant human erythropoietin on anaemia and
transfusion dependency in patients with ovarian carcinoma treated with
platinum-based chemotherapy. Med Oncol. 1998;15(3):174–82.
58 Throuvalas NA, Antonadou D, Boufi M, Lavey R. Erythropoietin de-
creases Transfusion Requirements during Radiochemotherapy.
Proc Am Soc Clin Oncol. 2000;19:2000.
59 Boogaerts M, Coiffier B, Kainz C. Impact of epoetin beta on quality of
life in patients with malignant disease. Br J Cancer. 2003;88(7):988–95.
60 Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K,
Hedenus M, et al. Randomized, double-blind, placebo-controlled trial
of recombinant human erythropoietin, epoetin Beta, in hematologic ma-
lignancies. J Clin Oncol. 2002;20(10):2486–94.
61 Quirt I, Micucci S, Moran LA, Pater J, Browman G. The role of recom-
binant human erythropoietin (EPO) in reducing red blood cell trans-
fusions and maintaining quality of life (QOL) in patients with lymph-
oma and solid tumors receiving cytotoxic chemotherapy. Results of
a randomized, double-blind, placebo-controlled clinical trial. Blood.
1996;88(10 (Suppl 1)):347a. Blood. 1996;88[10 (Suppl 1)], 347a.
62 Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V,
Vlahou I, et al. Prevention of anemia in patients with solid tumors
receiving platinum-based chemotherapy by recombinant human
Erythropoietin (rHuEpo): a prospective, open label, randomized trial
by the Hellenic Cooperative Oncology Group. Oncology.
2003;64(2):102–10.
63 Huddart RA, Welch RS, Chan S, Perren T, Atkinson R. A prospective
randomised comparative-group evaluation of epoetin alfa for the treat-
ment of anaemia in UK cancer patients receiving platinum-based
chemotherapy. [Miscellaneous]. Annals of Oncology Abstract Book of
the 27th ESMO Congress, Nice, France, 2002;13(Suppl 5):177.
Review article: Current opinion Swiss Med Wkly. 2013;143:w13776
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 7 of 11
64 INT-1. 2004. Department of Health and Human Services Food and Drug
Administration Center for Drug Evaluation and Research, Oncologic
Drugs Advisory Committee.
65 INT-3. 2004. Department of Health and Human Services Food and Drug
Administration Center for Drug Evaluation and Research, Oncologic
Drugs Advisory Committee.
66 P-174. 2004. Department of Health and Human Services Food and Drug
Administration Center for Drug Evaluation and Research, Oncologic
Drugs Advisory Committee.
67 ODAC 2003. 2004. Department of Health and Human Services Food
and Drug Administration Center for Drug Evaluation and Research,
Oncologic Drugs Advisory Committee.
68 Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O,
Hyde C, Engert A, Bohlius J. Erythropoietin or darbepoetin for patients
with cancer. Cochrane Database of Systematic Reviews 2012.
69 Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, Wil-
liamson PR. The impact of outcome reporting bias in randomised con-
trolled trials on a cohort of systematic reviews. BMJ. 2010;340:c365.
70 Poppe K, Doughty R, Yu C, Quintana M, Moller J, Klein A, et al.
Understanding differences in results from literature-based and individu-
al patient meta-analyses: An example from meta-analyses of observa-
tional data. Int J Cardiol. 2011;148:209–13.
71 McCormack K, Grant A, Scott N. Value of updating a systematic review
in surgery using individual patient data. Br J Surg. 2004;91(4):495–9.
72 DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et
al. Clinical trial registration: a statement from the International Com-
mittee of Medical Journal Editors. Archives of Otolaryngology – Head
& Neck Surgery. 2005;131(6):479–80.
73 International Committee of Medical Journal Editors (ICMJE), Laine C,
Horton R, De AC, Drazen JM, Frizelle FA, Godlee F, et al. Clinical tri-
al registration: looking back and moving ahead. [Danish]. Ugeskrift for
Laeger. 2007;169(26):2505–6.
74 Huic M, Marusic M, Marusic A. Completeness and changes in re-
gistered data and reporting bias of randomized controlled trials in
ICMJE journals after trial registration policy. PLoS ONE [Electronic
Resource] 2011;6(9):e25258.
75 Golder S, Loke YK, Bland M. Unpublished data can be of value in sys-
tematic reviews of adverse effects: methodological overview. [Review].
J Clin Epidemiol. 2010;63(10):1071–81.
76 FDA Amendments Act of 2007. http://frwebgate.access.gpo.gov/cgi-
bin/get-
doc.cgi?dbname=110_cong_public_laws&docid=f:publ085.110. Pdf
77 Wieseler B, McGauran N, Kaiser T. Finding studies on reboxetine: a
tale of hide and seek. BMJ. 2010;341:c4942.
78 Godlee F, Loder E. Missing clinical trial data: setting the record straight.
BMJ. 2010;341:c5641.
79 Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R,
et al. Neuraminidase inhibitors for preventing and treating influenza in
healthy adults and children. [Review]. Cochrane Database of Systemat-
ic Reviews 2012;1:CD008965.
80 Eichler H, Abadie E, Breckenridge H, Leufkens H, Rasi G. Open
clinical trial data for all? A view from regulators. PLoS.Med.
2012;9(4):e1001202.
81 European Medicines Agency widens public access to documents:
Policy on access to documents also sets out new approach for proactive
disclosure of documents. http://www.ema.europa.eu/ema/in-
dex.jsp?curl=pages/news_and_events/news/2010/11/
news_detail_001158.jsp&mid=WC0b01ac058004d5c1
82 Wieseler B, McGauran N, Kerekes M, Kaiser T. Access to regulatory
data from the European Medicines Agency: the times they are a-chan-
ging. Systematic Reviews 2012;1:50.
83 Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG. Preparing raw
clinical data for publication: guidance for journal editors, authors, and
peer reviewers. BMJ. 2010;340:c181.
84 Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-
Jeric K, et al. SPIRIT 2013 Statement: Defining Standard Protocol
Items for Clinical Trials. Ann Intern Med. 2013 Jan 8.
85 Guideline for industry: structure and content of clinical study reports.
http://www.fda.gov/downloads/regulatoryinformation/guidances/
ucm129456.pdf. 2013.
86 Humaidan P, Polyzos NP. (Meta)analyze this: Systematic reviews might
lose credibility. Nat Med. 2012;18(9):1321.
87 Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Ben-
nett C, Engert A. Recombinant human erythropoietin and overall sur-
vival in cancer patients: results of a comprehensive meta-analysis. J
Natl Cancer Inst. 2005;97(7):489–98.
88 Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Ef-
fects of epoetin alfa on hematologic parameters and quality of life
in cancer patients receiving nonplatinum chemotherapy: results of a
randomized, double-blind, placebo-controlled trial. J Clin Oncol.
2001;19(11):2865–74.
Review article: Current opinion Swiss Med Wkly. 2013;143:w13776
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 11
Figures (large format)
Figure 1
Forest plot for overall survival based on data from our first meta-analysis [12].
Figure 2
Funnel plot for overall survival based on data from our first meta-analysis [12].
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Figure 3
Forest plot for overall survival based on data from our first meta-analysis [12] adding missing studies and using results from individual patient
data review [27, 28].
Review article: Current opinion Swiss Med Wkly. 2013;143:w13776
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 10 of 11
Figure 4
Funnel plot for overall survival based on data from our first meta-analysis [12] adding missing studies and using results from individual patient
data review [27, 28].
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